Key Points
- Director Luke Evnin sold a total of about 422,425 shares in multiple December transactions for roughly $325,758 (including a Dec. 26 sale of 35,632 shares for $22,448.16), and still directly owns 2,659,280 shares after the sales.
- Shares of HOWL opened at $0.62 (down ~5.1%), the company has a market cap of about $30.15 million and a 52-week range of $0.56–$2.38 with 50‑ and 200‑day SMAs of $1.06 and $1.29.
- Analyst coverage is mixed with an average rating of Hold and an average price target of $3.75, and institutional investors own roughly 64.84% of the stock.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 16,310 shares of the firm's stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $0.65, for a total transaction of $10,601.50. Following the completion of the sale, the director owned 2,694,912 shares in the company, valued at $1,751,692.80. This represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Luke Evnin also recently made the following trade(s):
- On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66.
- On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $22,448.16.
- On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $44,999.64.
- On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $40,921.83.
- On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $11,380.62.
- On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total value of $15,275.40.
- On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total value of $25,294.80.
- On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.08, for a total value of $19,286.64.
- On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63.
- On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total transaction of $39,330.24.
Werewolf Therapeutics Stock Performance
HOWL opened at $0.62 on Tuesday. The company's 50 day moving average is $1.06 and its 200 day moving average is $1.29. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The company has a market cap of $30.15 million, a price-to-earnings ratio of -0.38 and a beta of 0.74. Werewolf Therapeutics, Inc. has a 12-month low of $0.56 and a 12-month high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.
Institutional Trading of Werewolf Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Quadrature Capital Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $28,000. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the 2nd quarter valued at approximately $48,000. Nuveen LLC bought a new stake in shares of Werewolf Therapeutics during the first quarter valued at approximately $71,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics during the first quarter valued at approximately $79,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Werewolf Therapeutics in the second quarter worth $92,000. Institutional investors own 64.84% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on HOWL shares. Bank of America lowered their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Tuesday, November 18th. Citizens Jmp cut Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, December 19th. Wedbush downgraded Werewolf Therapeutics from an "outperform" rating to a "neutral" rating and set a $1.00 price objective for the company. in a research note on Friday, December 19th. HC Wainwright decreased their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday, December 19th. Finally, Zacks Research downgraded shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 21st. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Werewolf Therapeutics has a consensus rating of "Hold" and an average target price of $3.75.
Read Our Latest Stock Report on HOWL
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
